|
Therapeuticsmd, Inc. (TXMD) Valoración de DCF
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
TherapeuticsMD, Inc. (TXMD) Bundle
¡Simplifique la valoración de TherapeuticsMD, Inc. (TXMD) con esta calculadora DCF personalizable! Con Real TherapeuticsMD, Inc. (TXMD) financieras y entradas de pronóstico ajustables, puede probar escenarios y descubrir TherapeuticsMD, Inc. (TXMD) valor razonable en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.6 | 64.9 | 87.0 | 70.0 | 1.3 | 1.1 | 1.0 | .9 | .7 | .6 |
| Revenue Growth, % | 0 | 30.67 | 34.03 | -19.54 | -98.14 | -13.24 | -13.24 | -13.24 | -13.24 | -13.24 |
| EBITDA | -156.3 | -149.5 | -78.6 | 11.9 | -8.4 | -.8 | -.7 | -.6 | -.6 | -.5 |
| EBITDA, % | -314.84 | -230.41 | -90.36 | 16.95 | -645.24 | -74.68 | -74.68 | -74.68 | -74.68 | -74.68 |
| Depreciation | 2.5 | 5.5 | .7 | 1.2 | .1 | .1 | .0 | .0 | .0 | .0 |
| Depreciation, % | 4.94 | 8.44 | 0.84645 | 1.71 | 9.37 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| EBIT | -158.8 | -154.9 | -79.3 | 10.7 | -8.5 | -.8 | -.7 | -.6 | -.6 | -.5 |
| EBIT, % | -319.78 | -238.84 | -91.21 | 15.24 | -654.61 | -75.19 | -75.19 | -75.19 | -75.19 | -75.19 |
| Total Cash | 160.8 | 80.5 | 65.1 | 38.1 | 4.3 | 1.0 | .8 | .7 | .6 | .5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 24.4 | 32.4 | 36.2 | .0 | 3.1 | .5 | .5 | .4 | .4 | .3 |
| Account Receivables, % | 49.14 | 49.92 | 41.61 | 0 | 237.33 | 48.13 | 48.13 | 48.13 | 48.13 | 48.13 |
| Inventories | 11.9 | 8.0 | 7.6 | .0 | .0 | .1 | .1 | .1 | .1 | .1 |
| Inventories, % | 23.89 | 12.32 | 8.77 | 0 | 0 | 9 | 9 | 9 | 9 | 9 |
| Accounts Payable | 19.2 | 21.1 | 3.4 | 2.2 | .0 | .2 | .2 | .1 | .1 | .1 |
| Accounts Payable, % | 38.64 | 32.48 | 3.88 | 3.09 | 2.07 | 16.03 | 16.03 | 16.03 | 16.03 | 16.03 |
| Capital Expenditure | -23.9 | -1.6 | -2.2 | -.4 | .0 | -.1 | -.1 | -.1 | -.1 | -.1 |
| Capital Expenditure, % | -48.12 | -2.46 | -2.56 | -0.50741 | 0 | -10.73 | -10.73 | -10.73 | -10.73 | -10.73 |
| Tax Rate, % | -32.76 | -32.76 | -32.76 | -32.76 | -32.76 | -32.76 | -32.76 | -32.76 | -32.76 | -32.76 |
| EBITAT | -176.7 | -179.6 | -94.6 | 1,111.9 | -11.3 | -.8 | -.7 | -.6 | -.6 | -.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -215.2 | -177.9 | -117.2 | 1,155.4 | -16.4 | 1.7 | -.7 | -.6 | -.6 | -.5 |
| WACC, % | 7.61 | 7.61 | 7.61 | 7.61 | 7.61 | 7.61 | 7.61 | 7.61 | 7.61 | 7.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.3 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -14 | |||||||||
| Present Terminal Value | -10 | |||||||||
| Enterprise Value | -10 | |||||||||
| Net Debt | 4 | |||||||||
| Equity Value | -14 | |||||||||
| Diluted Shares Outstanding, MM | 10 | |||||||||
| Equity Value Per Share | -1.29 |
What You Will Get
- Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: TherapeuticsMD, Inc. (TXMD) financial data pre-filled to kickstart your evaluation.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model that aligns with your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive Data: TherapeuticsMD’s historical financial statements and pre-filled projections.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Results: View TherapeuticsMD’s intrinsic value recalculating instantly.
- Detailed Visual Outputs: Dashboard graphs present valuation results and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based TXMD DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically calculates TherapeuticsMD’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator?
- Accuracy: Utilizes real TherapeuticsMD financial data for precise calculations.
- Flexibility: Allows users to easily adjust and experiment with input variables.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive design ensures accessibility for users without extensive financial modeling skills.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for analyzing TherapeuticsMD, Inc. (TXMD) stock.
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights to clients regarding TherapeuticsMD, Inc. (TXMD).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like TherapeuticsMD, Inc. (TXMD) are assessed in the market.
What the Template Contains
- Pre-Filled DCF Model: TherapeuticsMD’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate TherapeuticsMD’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.